Company Profile
Brii Biosciences focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate.
Its portfolio also includes Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA, Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B, and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in c for the treatment of HIV.
It also develops Soralimixinfor the treatment of multi-drug resistant or extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1 Epetraborole for oral treatment for patients with treatment-refractory mycobacterium avium complex (MAC) lung disease. Incorporated in 2017, Brii Biosciences is headquartered in Beijing, China.